A double-blind, cross-over trial with madopar HBS in patients with Parkinson's disease.

Abstract

Fourteen patients with Parkinson's disease and motor fluctuations were given 125 mg of Madopar HBS or placebo twice a day in addition to their optimal standard Madopar treatment in a double-blind, cross-over study. Clinical response was evaluated by the King's College Hospital Parkinson's Disease Rating Scale, the Mobility in Bed Scale and self-scoring diaries. A significant improvement with the drug was found according to the rating scales, whereas evaluation by self-scoring diaries showed no significant changes. In three patients we observed worsening of abnormal involuntary movements. The present trial suggests that a low dose of Madopar HBS can be useful in addition to levodopa therapy in some patients on long-term treatment.

• Authors: G De Michele, A Mengano, A Filla, L Trombetta, G Campanella
• Journal: Acta neurologica (Acta Neurol (Napoli)) Vol. 11 Issue 6 Pg. 408-14 (Dec 1989) ISSN: 0001-6276 [Print] Italy
• PMID: 2694799 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article)

Chemical References

• Drug Combinations
• Hydrazines
• benserazide, levodopa drug combination
• Levodopa
• Benserazide

Topics

• Adult
• Aged
• Benserazide (therapeutic use)
• Clinical Trials as Topic
• Double-Blind Method
• Drug Combinations (therapeutic use)
• Female
• Humans
• Hydrazines (therapeutic use)
• Levodopa (therapeutic use)
• Male
• Middle Aged
• Parkinson Disease, Secondary (drug therapy, physiopathology)